Ivan Zanoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ivan Zanoni has a total of 724 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Granucci
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, Milan, Italy
59 shared publications - Achille Broggi
Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), 13288 Marseille Cedex, France
18 shared publications - Marco Di Gioia
Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA
13 shared publications Maddalena Collini
Department of Physics, University of Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
10 shared publications- Roberto Spreafico
Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, Los Angeles, CA, USA
10 shared publications - Laura Sironi
Department of Physics, University of Milano-Bicocca, Milan, Italy
8 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Cell Research
- p. 1-2
No time to die: cell death predicts IBD relapse
- 8 October 2026
- Published by Springer Nature in Cell Research
- p. 1-2
Open AccessNo time to die: cell death predicts IBD relapse
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (122)
Regulation of inflammation by oxidized lipids
Host-derived lipids undergoing enzymatic or nonenzymatic oxidation play critical roles in regulating inflammation. Polyunsaturated fatty acids, cholesterol, and cholesterol intermediates can be enzymatically oxidized and serve as signaling mediators controlling tissue homeostasis and immunity. Spontaneously generated oxidized lipids, including nonenzymatically oxidized phospholipids (oxPLs), result from oxidative stress and accumulate during inflammation, affecting cellular metabolism, immune cell functions, and cell fate. These distinct classes of oxidized lipids not only share overlapping inflammatory roles but also exhibit divergent effects depending on their molecular structures and cellular targets. This Review highlights the double-edged nature of oxPLs: Although their transient production triggers protective responses, their accumulation sustains inflammation, contributing to tissue damage. We also discuss the emerging roles of oxPLs in cell death programs, immune cell activation, and stromal cell functions, which are critical processes favoring tumor growth. Overall, we highlight how oxidized lipids orchestrate immune responses and explore their contribution to infectious diseases and cancer.
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (122)
Regulation of inflammation by oxidized lipids
Host-derived lipids undergoing enzymatic or nonenzymatic oxidation play critical roles in regulating inflammation. Polyunsaturated fatty acids, cholesterol, and cholesterol intermediates can be enzymatically oxidized and serve as signaling mediators controlling tissue homeostasis and immunity. Spontaneously generated oxidized lipids, including nonenzymatically oxidized phospholipids (oxPLs), result from oxidative stress and accumulate during inflammation, affecting cellular metabolism, immune cell functions, and cell fate. These distinct classes of oxidized lipids not only share overlapping inflammatory roles but also exhibit divergent effects depending on their molecular structures and cellular targets. This Review highlights the double-edged nature of oxPLs: Although their transient production triggers protective responses, their accumulation sustains inflammation, contributing to tissue damage. We also discuss the emerging roles of oxPLs in cell death programs, immune cell activation, and stromal cell functions, which are critical processes favoring tumor growth. Overall, we highlight how oxidized lipids orchestrate immune responses and explore their contribution to infectious diseases and cancer.
- 4 August 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (8) , 1077-1103
Metabolic danger signals: TCA cycle metabolites regulate immunity and disease
- 4 August 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (8) , 1077-1103
Metabolic danger signals: TCA cycle metabolites regulate immunity and disease
- 6 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (8)
Friend or foe? IFNλ drives fibrosis.
Type III IFNs, or IFNλ, are pleiotropic immune mediators that mostly work at mucosal surfaces by signaling in epithelial cells and selected immune cells. Zhou, Zhang, and colleagues (https://doi.org/10.1084/jem.20251858) demonstrate that IFNλ also signals in kidney fibroblasts sustaining renal fibrosis.
- 6 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (8)
Friend or foe? IFNλ drives fibrosis.
Type III IFNs, or IFNλ, are pleiotropic immune mediators that mostly work at mucosal surfaces by signaling in epithelial cells and selected immune cells. Zhou, Zhang, and colleagues (https://doi.org/10.1084/jem.20251858) demonstrate that IFNλ also signals in kidney fibroblasts sustaining renal fibrosis.
- Open Access
- 22 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (6) , 1130-1144
A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines
The activation of pattern recognition receptors (PRRs) orchestrates inflammation and regulates adaptive immunity. To test whether tuning inflammation through PRR stimulation enhanced the efficacy of mRNA vaccines, we combined an mRNA-based vaccine generated against the ancestral spike protein of SARS-CoV-2 with mannadjuvant, a formulation of fungal mannan and aluminum hydroxide targeting the PRR dectin-2. In mice and non-human primates, mannadjuvant increased the magnitude and durability of the response elicited by the mRNA-based vaccine, and it also led to the induction of neutralizing antibodies directed against variants of concern with a high escape capacity, overcoming antigenic imprinting. Mechanistically, prolonged type I interferon (IFN) production and potentiated interleukin-1 (IL-1) signaling locally within the draining lymph node in mice or in human cells were necessary and sufficient to exert the effect of mannadjuvant. Our data indicate that antifungal PRRs can be harnessed to create more potent and durable mRNA-based vaccines.
- 22 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (6) , 1130-1144
Open AccessA glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines
The activation of pattern recognition receptors (PRRs) orchestrates inflammation and regulates adaptive immunity. To test whether tuning inflammation through PRR stimulation enhanced the efficacy of mRNA vaccines, we combined an mRNA-based vaccine generated against the ancestral spike protein of SARS-CoV-2 with mannadjuvant, a formulation of fungal mannan and aluminum hydroxide targeting the PRR dectin-2. In mice and non-human primates, mannadjuvant increased the magnitude and durability of the response elicited by the mRNA-based vaccine, and it also led to the induction of neutralizing antibodies directed against variants of concern with a high escape capacity, overcoming antigenic imprinting. Mechanistically, prolonged type I interferon (IFN) production and potentiated interleukin-1 (IL-1) signaling locally within the draining lymph node in mice or in human cells were necessary and sufficient to exert the effect of mannadjuvant. Our data indicate that antifungal PRRs can be harnessed to create more potent and durable mRNA-based vaccines.
- 14 May 2026
- Published by Elsevier in Current Opinion in Immunology
- Vol. 100, 102787
Won’t you be my neighbor? Control of the immune response by stromal and immune cell microenvironments within the lymph node
- 14 May 2026
- Published by Elsevier in Current Opinion in Immunology
- Vol. 100, 102787
Won’t you be my neighbor? Control of the immune response by stromal and immune cell microenvironments within the lymph node
- Open Access
- 27 April 2026
- Published by Annual Reviews in Annual Review of Immunology
- Vol. 44 (1) , 121-147
Molecular, Cellular, Tissue, and Organismal Functions of Type III Interferons
Type III interferons are essential immune mediators playing pleiotropic roles during health and disease. In this review, we highlight the molecular and cellular pathways that lead to the production of type III interferons. We also describe their exquisite capacity to act at primary barrier tissues such as those in the intestine, airways, urogenital tract, and skin, as well as to act in other organs such as the liver and thymus. We characterize the activity of type III interferons on distinct cell types in different tissues and organs and detail their impact for the host in the context of viral, bacterial, helminth, and fungal infections. Additionally, we illustrate roles of type III interferons during the development of inflammatory diseases such as inflammatory bowel disease, acute respiratory distress syndrome, asthma, solid tumors, and lupus. Overall, we summarize the dichotomous roles played by this class of interferons and highlight the knowledge gaps that must be addressed to harness type III interferons against multiple human diseases.
- 27 April 2026
- Published by Annual Reviews in Annual Review of Immunology
- Vol. 44 (1) , 121-147
Open AccessMolecular, Cellular, Tissue, and Organismal Functions of Type III Interferons
Type III interferons are essential immune mediators playing pleiotropic roles during health and disease. In this review, we highlight the molecular and cellular pathways that lead to the production of type III interferons. We also describe their exquisite capacity to act at primary barrier tissues such as those in the intestine, airways, urogenital tract, and skin, as well as to act in other organs such as the liver and thymus. We characterize the activity of type III interferons on distinct cell types in different tissues and organs and detail their impact for the host in the context of viral, bacterial, helminth, and fungal infections. Additionally, we illustrate roles of type III interferons during the development of inflammatory diseases such as inflammatory bowel disease, acute respiratory distress syndrome, asthma, solid tumors, and lupus. Overall, we summarize the dichotomous roles played by this class of interferons and highlight the knowledge gaps that must be addressed to harness type III interferons against multiple human diseases.
- Open Access
- 11 November 2025
- Published by Elsevier in Trends in Immunology
- Vol. 47 (2) , 119-129
Post-translational modifications of NLRP3: to prime or not to prime?
- 11 November 2025
- Published by Elsevier in Trends in Immunology
- Vol. 47 (2) , 119-129
Open AccessPost-translational modifications of NLRP3: to prime or not to prime?
- Top Cited Papers
Interferons in health and disease